Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Twelve patients with non-insulin dependent diabetes mellitus (NIDDM) under secondary failure to sulfonylureas were studied to evaluate the effects of subcutaneous glucagon-like peptide-1(7-36)amide (GLP-1) on (a) the gastric emptying pattern of a solid meal (250 kcal) and (b) the glycemic and endocrine responses to this solid meal and an oral glucose tolerance test (OGTT, 300 kcal). 0.5 nmol/kg of GLP-1 or placebo were subcutaneously injected 20 min after meal ingestion. GLP-1 modified the pattern of gastric emptying by prolonging the time to reach maximal emptying velocity (lag period) which was followed by an acceleration in the post-lag period. The maximal emptying velocity and the emptying half-time remained unaltered. With both meals, GLP-1 diminished the postprandial glucose peak, and reduced the glycemic response during the first two postprandial hours by 54.5% (solid meal) and 32.7% (OGTT) (P < 0.05). GLP-1 markedly stimulated insulin secretion with an effect lasting for 105 min (solid meal) or 150 min (OGTT). The postprandial increase of plasma glucagon was abolished by GLP-1. GLP-1 diminished the postprandial release of pancreatic polypeptide. The initial and transient delay of gastric emptying, the enhancement of postprandial insulin release, and the inhibition of postprandial glucagon release were independent determinants (P < 0.002) of the postprandial glucose response after subcutaneous GLP-1. An inhibition of efferent vagal activity may contribute to the inhibitory effect of GLP-1 on gastric emptying.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 2×
“However, as it is known from studies with application of exogenous GLP-1(7–36)amide (Deacon et al. 1995b, Gutniak et al. 1996), bioactive GLP-1(7– 36)amide parallels the time course of total truncated GLP-1 immunoreactivity, but the elevation lasts for a shorter period.”
BackgroundMethodTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Herrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597
Self-citationWillms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502 · cited 1×
“In contrast to recently published studies in patients with NIDDM suggesting intravenous (Willms et al. 1996) or preprandially subcutaneously injected GLP-1 (Nauck et al. 1996) to cause a near complete inhibition of gastric emptying of liquid meals, a complete inhibition after subcutaneous GLP-1 did…”
ResultGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 1×
“Receptors for GLP-1 are present in circumventricular organs like the subfornical organ, the nucleus of the solitary tract and the area postrema (Göke et al. 1995).”
BackgroundPancreatic Polypeptide: A Hormone Under Vagal Control
Schwartz, T. W. (1983) · Gastroenterology · doi:10.1016/s0016-5085(83)80027-4 · Cited by 426 · cited 1×
“Intestinal stimulation of PP release requires stimulation of enteropancreatic cholinergic reflexes by duodenal delivery of nutrients (Schwartz 1983).”
BackgroundInsulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects
Nathan, D. M., Schreiber, E., Fogel, H., Mojsov, S., & Habener, J. F. (1992) · Diabetes Care · doi:10.2337/diacare.15.2.270 · Cited by 289
Wettergren, A., Petersen, H., ørskov, C., Christiansen, J., Sheikh, S. P., & Holst, J. J. (1994) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529409092462 · Cited by 133 · cited 1×
“This concept is compatible with GLP-1 inhibiting gastric acid secretion in response to sham feeding (Wettergren et al. 1994).”
Result
Cited by
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
“Activation of GLP-1R signaling by GLP-1RAs improves glucose control by enhancing glucose-stimulated insulin secretion [3,4], delaying gastric transit [5,6], and decreasing plasma glucagon levels [7], and reduces body weight by activating anorexigenic pathways in the brain [8].”
BackgroundHansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Havel, P. J. (2001) · Experimental Biology and Medicine · doi:10.1177/153537020122601102 · Cited by 481
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
“The mechanisms underlying the GLP-1 effects on gastric motility and acid secretion involve an inhibition of vagal activity, as indicated by the suppression of pancreatic polypeptide release during GLP-1 administration [117].”
BackgroundGLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans
Näslund, E., Bogefors, J., Skogar, S., Grybäck, P., Jacobsson, H., Holst, J. J., & Hellström, P. M. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.3.r910 · Cited by 284
Schirra, J., Nicolaus, M., Roggel, R., Katschinski, M., Storr, M., Woerle, H. J., & Göke, B. (2006) · Gut · doi:10.1136/gut.2004.059741 · Cited by 277
Self-citationExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Self-citationDelgado-Aros, S., Kim, D.-Y., Burton, D. D., Thomforde, G. M., Stephens, D., Brinkmann, B. H., Vella, A., & Camilleri, M. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2002.282.3.g424 · Cited by 235
“However, GLP-1 also exerts several effects on the upper digestive tract: inhibition of gastric acid and pancreatic exocrine secretions (42–44) and delay in gastric emptying for liquids and solids in health (28) and diabetes (29).”
BackgroundHellström, P. M., Näslund, E., Edholm, T., Schmidt, P. T., Kristensen, J., Theodorsson, E., Holst, J. J., & Efendic, S. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.01079.x · Cited by 160
Meier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146
Schirra, J., Houck, P., Wank, U., Arnold, R., Göke, B., & Katschinski, M. (2000) · Gut · doi:10.1136/gut.46.5.622 · Cited by 145
Self-citationEffects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138
Schirra, J., Wank, U., Arnold, R., Göke, B., & Katschinski, M. (2002) · Gut · doi:10.1136/gut.50.3.341 · Cited by 130
Self-citationEffects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus
VELLA, A., LEE, J. S., CAMILLERI, M., SZARKA, L. A., BURTON, D. D., ZINSMEISTER, A. R., RIZZA, R. A., & KLEIN, P. D. (2002) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2002.00311.x · Cited by 112
Quddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.791 · Cited by 111
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
“Mechanistically, GLP-1 decreases the time to reach maximum gastric emptying speed, while maximum velocity is not altered [80,81].”
BackgroundZhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01198-4 · Cited by 55
Langmach Wegeberg, A., Hansen, C. S., Farmer, A. D., Karmisholt, J. S., Drewes, A. M., Jakobsen, P. E., Brock, B., & Brock, C. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620925968 · Cited by 28
“A similar pattern may be present in type 1 diabetes.(27) Due to the nature of the wireless motility capsule, however, we could not observe this lag period in our data.”
Background
Metadata
- Authors
- Schirra, J., Leicht, P., Hildebrand, P., Beglinger, C., Arnold, R., Goke, B., & Katschinski, M.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 1998-01-01
- Volume
- 156
- Issue
- 1
- Pages
- 177-186
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W1982133101
- Cited by
- 65
- References
- 9
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.